Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
Curr Opin Psychiatry ; 36(2): 96-103, 2023 03 01.
Article in English | MEDLINE | ID: mdl-36705008

ABSTRACT

PURPOSE OF REVIEW: Down syndrome regression disorder (DSRD) is a symptom cluster consisting of neuropsychiatric regression without cause. Although knowledge of this condition has accelerated over the last decade, prior studies have been limited by heterogenous nomenclature, diagnostic approaches and therapeutic interventions. This review highlights recent advances in the diagnosis and clinical approach to DSRD and reviews the most up-to-date literature on therapeutic interventions for this condition. RECENT FINDINGS: Several multicentre studies have reported exciting findings on the presence of neurodiagnostic study abnormalities and responses to a variety of therapeutics, including psychotropics (including benzodiazepines), electroconvulsive therapy and immunotherapy. Differential response rates have been observed in the presence and absence of a variety of clinical and diagnostic factors. SUMMARY: Individuals with DSRD are responsive to a variety of psychiatric pharmacotherapy and immunotherapy underscoring this phenotype may have multiple causes. Multidisciplinary care is helpful in the evaluation and management of individuals with this condition.


Subject(s)
Down Syndrome , Electroconvulsive Therapy , Humans , Down Syndrome/therapy , Psychotropic Drugs , Benzodiazepines/therapeutic use
2.
Am J Med Genet A ; 185(1): 286-299, 2021 01.
Article in English | MEDLINE | ID: mdl-33073471

ABSTRACT

Pneumonia and respiratory infections impact infants and children with Down syndrome; pneumonia is a leading cause of mortality in adults with Down syndrome. We aimed to review the literature to evaluate gaps and address key questions. A series of key questions were formulated a priori to inform the search strategy and review process; addressed prevalence, severity, etiology, risk factors, preventive methods, screening, and financial costs, potential benefits or harms of screening. Using the National Library of Medicine database, PubMed, detailed literature searches on pneumonia and respiratory infections in Down syndrome were performed. Previously identified review articles were also assessed. The quality of available evidence was then evaluated and knowledge gaps were identified. Forty-two relevant original articles were identified which addressed at least one key question. Study details including research design, internal validity, external validity, and relevant results are presented. Pneumonia and respiratory infections are more prevalent and more severe in individuals with Down syndrome compared to healthy controls through literature review, yet there are gaps in the literature regarding the etiology of pneumonia, the infectious organism, risk factors for infection, and to guide options for prevention and screening. There is urgent need for additional research studies in Down syndrome, especially in the time of the current COVID-19 pandemic.


Subject(s)
Down Syndrome/epidemiology , Pneumonia/epidemiology , Respiratory Tract Infections/epidemiology , Adult , COVID-19/epidemiology , Down Syndrome/complications , Down Syndrome/mortality , Down Syndrome/therapy , Humans , Pandemics , Pneumonia/complications , Pneumonia/mortality , Pneumonia/therapy , Respiratory Tract Infections/complications , Respiratory Tract Infections/mortality , Respiratory Tract Infections/pathology , Risk Factors , SARS-CoV-2/physiology , Severity of Illness Index
3.
JAMA ; 324(15): 1543-1556, 2020 10 20.
Article in English | MEDLINE | ID: mdl-33079159

ABSTRACT

Importance: Down syndrome is the most common chromosomal condition, and average life expectancy has increased substantially, from 25 years in 1983 to 60 years in 2020. Despite the unique clinical comorbidities among adults with Down syndrome, there are no clinical guidelines for the care of these patients. Objective: To develop an evidence-based clinical practice guideline for adults with Down syndrome. Evidence Review: The Global Down Syndrome Foundation Medical Care Guidelines for Adults with Down Syndrome Workgroup (n = 13) developed 10 Population/Intervention/ Comparison/Outcome (PICO) questions for adults with Down syndrome addressing multiple clinical areas including mental health (2 questions), dementia, screening or treatment of diabetes, cardiovascular disease, obesity, osteoporosis, atlantoaxial instability, thyroid disease, and celiac disease. These questions guided the literature search in MEDLINE, EMBASE, PubMed, PsychINFO, Cochrane Library, and the TRIP Database, searched from January 1, 2000, to February 26, 2018, with an updated search through August 6, 2020. Using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) methodology and the Evidence-to-Decision framework, in January 2019, the 13-member Workgroup and 16 additional clinical and scientific experts, nurses, patient representatives, and a methodologist developed clinical recommendations. A statement of good practice was made when there was a high level of certainty that the recommendation would do more good than harm, but there was little direct evidence. Findings: From 11 295 literature citations associated with 10 PICO questions, 20 relevant studies were identified. An updated search identified 2 additional studies, for a total of 22 included studies (3 systematic reviews, 19 primary studies), which were reviewed and synthesized. Based on this analysis, 14 recommendations and 4 statements of good practice were developed. Overall, the evidence base was limited. Only 1 strong recommendation was formulated: screening for Alzheimer-type dementia starting at age 40 years. Four recommendations (managing risk factors for cardiovascular disease and stroke prevention, screening for obesity, and evaluation for secondary causes of osteoporosis) agreed with existing guidance for individuals without Down syndrome. Two recommendations for diabetes screening recommend earlier initiation of screening and at shorter intervals given the high prevalence and earlier onset in adults with Down syndrome. Conclusions and Relevance: These evidence-based clinical guidelines provide recommendations to support primary care of adults with Down syndrome. The lack of high-quality evidence limits the strength of the recommendations and highlights the need for additional research.


Subject(s)
Down Syndrome/therapy , Adult , Alzheimer Disease/complications , Alzheimer Disease/epidemiology , Cardiovascular Diseases/complications , Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/prevention & control , Comorbidity , Diabetes Complications/epidemiology , Down Syndrome/complications , Evidence-Based Medicine , Humans , Mass Screening , Obesity/complications
4.
Am J Med Genet A ; 182(7): 1832-1845, 2020 07.
Article in English | MEDLINE | ID: mdl-32338447

ABSTRACT

Adults with Down syndrome (DS) represent a unique population who are in need of clinical guidelines to address their medical care. Many of these conditions are of public health importance with the potential to develop screening recommendations to improve clinical care for this population. Our workgroup previously identified and prioritized co-occurring medical conditions in adults with DS. In this study, we again performed detailed literature searches on an additional six medical conditions of clinical importance. A series of key questions (KQ) were formulated a priori to guide the literature search strategy. Our KQs focused on disease prevalence, severity, risk-factors, methodologies for screening/evaluation, impact on morbidity, and potential costs/benefits. The available evidence was extracted, evaluated and graded on quality. The number of participants and the design of clinical studies varied by condition and were often inadequate for answering most of the KQ. Based upon our review, we provide a summary of the findings on hip dysplasia, menopause, acquired cardiac valve disease, type 2 diabetes mellitus, hematologic disorders, and dysphagia. Minimal evidence demonstrates significant gaps in our clinical knowledge that compromises clinical decision-making and management of these medically complex individuals. The creation of evidence-based clinical guidance for this population will not be possible until these gaps are addressed.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Down Syndrome/drug therapy , Hematologic Diseases/drug therapy , Adult , Clinical Decision-Making , Delivery of Health Care/trends , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/epidemiology , Down Syndrome/complications , Down Syndrome/epidemiology , Down Syndrome/pathology , Female , Guidelines as Topic , Hematologic Diseases/complications , Hematologic Diseases/epidemiology , Hematologic Diseases/pathology , Humans , Male , Mass Screening , Risk Factors
6.
Am J Med Genet A ; 176(1): 116-133, 2018 01.
Article in English | MEDLINE | ID: mdl-29130597

ABSTRACT

Adults with Down syndrome (DS) represent a unique population who are in need of clinical guidelines to address their medical care. The United States Preventive Service Task Force (USPSTF) has developed criteria for prioritizing conditions of public health importance with the potential for providing screening recommendations to improve clinical care. The quality of existing evidence needed to inform clinical guidelines has not been previously reviewed. Using the National Library of Medicine (NLM) database PubMed, we first identified 18 peer reviewed articles that addressed co-occurring medical conditions in adults with DS. Those conditions discussed in over half of the articles were prioritized for further review. Second, we performed detailed literature searches on these specific conditions. To inform the search strategy and review process a series of key questions were formulated a priori. The quality of available evidence was then graded and knowledge gaps were identified. The number of participating adults and the design of clinical studies varied by condition and were often inadequate for answering all of our key questions. We provide data on thyroid disease, cervical spine disease, hearing impairment, overweight-obesity, sleep apnea, congenital heart disease, and osteopenia-osteoporosis. Minimal evidence demonstrates massive gaps in our clinical knowledge that compromises clinical decision-making and management of these medically complex individuals. The development of evidence-based clinical guidance will require an expanded clinical knowledge-base in order to move forward.


Subject(s)
Down Syndrome/epidemiology , Adult , Age Factors , Biomedical Research , Comorbidity , Delivery of Health Care , Disease Management , Down Syndrome/therapy , Evidence-Based Medicine , Humans , Practice Guidelines as Topic , Prevalence
7.
J Alzheimers Dis ; 61(2): 631-644, 2018.
Article in English | MEDLINE | ID: mdl-29254096

ABSTRACT

BACKGROUND: The Down syndrome (DS) population is genetically predisposed to amyloid-ß protein precursor overproduction and Alzheimer's disease (AD). OBJECTIVE: The temporal ordering and spatial association between amyloid-ß, glucose metabolism, and gray matter (GM) volume in the DS population can provide insight into those associations in the more common sporadic AD. METHODS: Twenty-four adults (13 male, 11 female; 39±7 years) with DS underwent [11C]PiB, [18F]FDG, and volumetric MRI scans. Voxel-wise associations between PiB SUVR, FDG SUVR, and GM volume were investigated, with and without individual adjustments for variables of interest. RESULTS: Positive associations of PiB and age were widespread throughout the neocortex and striatum. Negative associations of FDG and age (frontal, parietal, and temporal cortex) and of GM volume and age (frontal and insular cortex) were observed. PiB and FDG were negatively associated in parietal cortex, after adjustment for GM volume. CONCLUSIONS: In adults with DS, early amyloid-ß accumulation in the striatum is divergent from sporadic AD; however, despite the early striatal amyloid-ß, glucose hypometabolism was confined to the typical AD-associated regions, which occurs similarly in autosomal dominant AD. Importantly, the glucose hypometabolism was not explained solely by increased partial volume effect due to GM volume reductions.


Subject(s)
Alzheimer Disease/complications , Amyloid beta-Peptides/metabolism , Down Syndrome/complications , Gray Matter/diagnostic imaging , Adult , Alzheimer Disease/metabolism , Alzheimer Disease/physiopathology , Down Syndrome/metabolism , Down Syndrome/physiopathology , Female , Fluorodeoxyglucose F18 , Humans , Linear Models , Longitudinal Studies , Magnetic Resonance Imaging , Male , Middle Aged , Positron-Emission Tomography , Radiopharmaceuticals , United States
8.
Neurobiol Aging ; 58: 68-76, 2017 10.
Article in English | MEDLINE | ID: mdl-28715661

ABSTRACT

Adults with Down syndrome (DS) have a high incidence of Alzheimer's disease (AD), providing a unique opportunity to explore the early, preclinical stages of AD neuropathology. We examined change in brain amyloid-ß accumulation via the positron emission tomography tracer [11C] Pittsburgh compound B (PiB) across 2 data collection cycles, spaced 3 years apart, and decline in cognitive functioning in 58 adults with DS without clinical AD. PiB retention increased in the anterior cingulate gyrus, precuneus cortex, parietal cortex, and anterior ventral striatum. Across the 2 cycles, 14 (27.5%) participants were consistently PiB+, 31 (60.8%) were consistently PiB-, and 6 (11.7%) converted from PiB- at cycle 1 to PiB+ at cycle 2. Increased global amyloid-ß was related to decline in verbal episodic memory, visual episodic memory, executive functioning, and fine motor processing speed. Participants who were consistently PiB+ demonstrated worsening of episodic memory, whereas participants who were consistently PiB- evidenced stable or improved performance. Amyloid-ß accumulation may be a contributor to or biomarker of declining cognitive functioning in preclinical AD in DS.


Subject(s)
Amyloid beta-Peptides/metabolism , Brain/metabolism , Cognition/physiology , Cognitive Dysfunction/etiology , Cognitive Dysfunction/metabolism , Down Syndrome/metabolism , Down Syndrome/psychology , Adult , Alzheimer Disease/etiology , Alzheimer Disease/metabolism , Aniline Compounds , Brain/diagnostic imaging , Executive Function/physiology , Female , Humans , Male , Memory, Episodic , Middle Aged , Phenanthrolines , Positron-Emission Tomography , Thiazoles , Time Factors
9.
Article in English | MEDLINE | ID: mdl-28603769

ABSTRACT

INTRODUCTION: Down syndrome (DS) arises from a triplication of chromosome 21, causing overproduction of the amyloid precursor protein and predisposes individuals to early Alzheimer's disease (AD). METHODS: Fifty-two nondemented adults with DS underwent two cycles of carbon 11-labeled Pittsburgh compound B ([11C]PiB) and T1 weighted magnetic resonance imaging (MRI) scans 3.0 ± 0.6 years apart. Standard uptake value ratio (SUVR) images (50-70 minutes; cerebellar gray matter [GM]) and GM volumes were analyzed in standardized space (Montreal Neurological Institute space). RESULTS: 85% of PiB(-) subjects remained PiB(-), whereas 15% converted to PiB(+), predominantly in the striatum. None reverted from PiB(+) to PiB(-). Increases in SUVR were distributed globally, but there were no decreases in GM volume. The PiB positivity groups differed in the percent rate of change in SUVR [PiB(-): 0.5%/year, PiB converters: 4.9%/year, and PiB(+): 3.7%/year], but not in GM volume. DISCUSSION: Despite the characteristic striatum-first pattern, the global rate of amyloid accumulation differs by pre-existing amyloid burden and precedes atrophy or dementia in the DS population, similar to general AD progression.

10.
Intellect Dev Disabil ; 55(2): 97-109, 2017 04.
Article in English | MEDLINE | ID: mdl-28375797

ABSTRACT

The present study examined leisure activity and its association with caregiver involvement (i.e., residence and time spent with primary caregiver) in 62 middle-aged and older adults with Down syndrome (aged 30-53 years). Findings indicated that middle-aged and older adults with Down syndrome frequently participated in social and passive leisure activities, with low participation in physical and mentally stimulating leisure activities. Residence and time spent with primary caregiver were associated with participation in physical leisure activity. The findings suggest a need for support services aimed at increasing opportunities for participating in physical and mentally stimulating leisure activity by middle-aged and older adults with Down syndrome. These support services should partner with primary caregivers in order to best foster participation in physical leisure activity.


Subject(s)
Caregivers/psychology , Down Syndrome/psychology , Leisure Activities , Adult , Female , Humans , Male , Middle Aged
11.
J Gen Intern Med ; 32(6): 595-596, 2017 06.
Article in English | MEDLINE | ID: mdl-28247167
13.
Alzheimers Dement ; 12(4): 380-90, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26079411

ABSTRACT

INTRODUCTION: In Down syndrome (DS), the overproduction of amyloid precursor protein is hypothesized to predispose young adults to early expression of Alzheimer-like neuropathology. METHODS: PET imaging with carbon 11-labeled Pittsburgh compound B examined the pattern of amyloid-ß deposition in 68 nondemented adults with DS (30-53 years) to determine the relationship between deposition and normal aging. Standard uptake value ratio (SUVR) images were created with cerebellar gray matter as the reference region. RESULTS: Multiple linear regression revealed slight but highly significant (corrected P < .05) positive correlations between SUVR and age. The striatum showed the strongest correlation, followed by precuneus, parietal cortex, anterior cingulate, frontal cortex, and temporal cortex. CONCLUSION: There is an age-related amyloid-ß deposition in the DS population, but as a pattern of elevated cortical retention becomes apparent, the correlation of SUVR with age ceases to be significant. Factors unrelated to aging may drive an increase in deposition during early Alzheimer's disease pathogenesis.


Subject(s)
Aging/metabolism , Brain/diagnostic imaging , Brain/metabolism , Down Syndrome/diagnostic imaging , Down Syndrome/metabolism , Adult , Aniline Compounds , Apolipoproteins E/genetics , Carbon Radioisotopes , Cohort Studies , Down Syndrome/genetics , Female , Humans , Linear Models , Magnetic Resonance Imaging , Male , Middle Aged , Positron-Emission Tomography , Radiopharmaceuticals , Thiazoles
14.
BMJ ; 349: g5596, 2014 Sep 30.
Article in English | MEDLINE | ID: mdl-25269800
15.
Alzheimers Dement ; 8(6): 496-501, 2012 Nov.
Article in English | MEDLINE | ID: mdl-23102120

ABSTRACT

Down syndrome (DS) is one of the most common causes of intellectual disability. Although DS accounts for only 15% of all individuals with intellectual disabilities, adults with DS account for approximately 60% of individuals with intellectual disabilities and Alzheimer's disease. This is thought to be because of overproduction of the ß-amyloid (Aß) protein due to trisomy for the Aß precursor protein gene on chromosome 21. Pittsburgh compound B (PiB) is a noninvasive in vivo positron emission tomography tracer used to image amyloid deposition in living humans. Studies using PiB have shown an age-dependent asymptomatic amyloid deposition in more than 20% of the cognitively normal elderly population. Presymptomatic carriers of presenilin (PS-1) and Aß precursor protein gene mutations who are destined to develop Alzheimer's disease also show preclinical amyloid deposition. This report describes a pilot study involving the use of PiB in seven adults with DS (age: 20-44 years). Compared with objective cutoffs for amyloid positivity in older non-DS cognitively normal control subjects, only two of the seven DS subjects (age: 38 and 44 years) showed increased PiB retention. The remaining five subjects aged between 20 and 35 years showed no detectable increase in PiB retention. Interestingly, the two subjects who showed elevated PiB retention showed a striatal-predominant pattern similar to that previously reported for PS-1 mutation carriers. These results demonstrate the feasibility of conducting PiB positron emission tomography scanning in this special population, and suggest a link between Aß overproduction and early striatal deposition of fibrillar Aß.


Subject(s)
Amyloidogenic Proteins/analysis , Aniline Compounds , Brain/diagnostic imaging , Down Syndrome/diagnostic imaging , Radiopharmaceuticals , Thiazoles , Adult , Female , Humans , Male , Neuroimaging/methods , Pilot Projects , Positron-Emission Tomography , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...